166 related articles for article (PubMed ID: 34589578)
1. An oral cancer vaccine using a
Kitagawa K; Tatsumi M; Kato M; Komai S; Doi H; Hashii Y; Katayama T; Fujisawa M; Shirakawa T
Mol Ther Oncolytics; 2021 Sep; 22():592-603. PubMed ID: 34589578
[TBL] [Abstract][Full Text] [Related]
2. An oral cancer vaccine using Bifidobacterium vector augments combination of anti-PD-1 and anti-CTLA-4 antibodies in mouse renal cell carcinoma model.
Ueki H; Kitagawa K; Kato M; Yanase S; Okamura Y; Bando Y; Hara T; Terakawa T; Furukawa J; Nakano Y; Fujisawa M; Shirakawa T
Sci Rep; 2023 Jun; 13(1):9994. PubMed ID: 37340017
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effect of oral cancer vaccine with Bifidobacterium delivering WT1 protein to gut immune system is superior to WT1 peptide vaccine.
Shirakawa T; Kitagawa K
Hum Vaccin Immunother; 2018 Jan; 14(1):159-162. PubMed ID: 29048978
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Development of a WT1 Oral Cancer Vaccine Using a Bacterial Vector to Treat Castration-Resistant Prostate Cancer.
Kitagawa K; Gonoi R; Tatsumi M; Kadowaki M; Katayama T; Hashii Y; Fujisawa M; Shirakawa T
Mol Cancer Ther; 2019 May; 18(5):980-990. PubMed ID: 30824610
[TBL] [Abstract][Full Text] [Related]
5. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
6. Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.
Rouanne M; Roumiguié M; Houédé N; Masson-Lecomte A; Colin P; Pignot G; Larré S; Xylinas E; Rouprêt M; Neuzillet Y
World J Urol; 2018 Nov; 36(11):1727-1740. PubMed ID: 29855698
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).
Yoneda K; Imanishi N; Ichiki Y; Tanaka F
J UOEH; 2018; 40(2):173-189. PubMed ID: 29925736
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model.
Kaumaya PTP; Guo L; Overholser J; Penichet ML; Bekaii-Saab T
Oncoimmunology; 2020 Oct; 9(1):1818437. PubMed ID: 33117602
[TBL] [Abstract][Full Text] [Related]
10. Synergistic anti-tumor efficacy by combination therapy of a self-assembled nanogel vaccine with an immune checkpoint anti-PD-1 antibody.
Miura R; Sawada SI; Mukai SA; Sasaki Y; Akiyoshi K
RSC Adv; 2020 Feb; 10(14):8074-8079. PubMed ID: 35497849
[TBL] [Abstract][Full Text] [Related]
11. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
12. Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy.
Collins JM; Redman JM; Gulley JL
Expert Rev Vaccines; 2018 Aug; 17(8):697-705. PubMed ID: 30058393
[TBL] [Abstract][Full Text] [Related]
13. A Novel Anti-PD-L1 Vaccine for Cancer Immunotherapy and Immunoprevention.
Chen J; Liu H; Jehng T; Li Y; Chen Z; Lee KD; Shen HT; Jones L; Huang XF; Chen SY
Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31805690
[TBL] [Abstract][Full Text] [Related]
14. Vaccine immunotherapy with ARNAX induces tumor-specific memory T cells and durable anti-tumor immunity in mouse models.
Takeda Y; Yoshida S; Takashima K; Ishii-Mugikura N; Shime H; Seya T; Matsumoto M
Cancer Sci; 2018 Jul; 109(7):2119-2129. PubMed ID: 29791768
[TBL] [Abstract][Full Text] [Related]
15. A novel cancer vaccine with the ability to simultaneously produce anti-PD-1 antibody and GM-CSF in cancer cells and enhance Th1-biased antitumor immunity.
Tian H; Shi G; Wang Q; Li Y; Yang Q; Li C; Yang G; Wu M; Xie Q; Zhang S; Yang Y; Xiang R; Yu D; Wei Y; Deng H
Signal Transduct Target Ther; 2016; 1():16025. PubMed ID: 29263903
[TBL] [Abstract][Full Text] [Related]
16. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancer.
Gómez de Liaño Lista A; van Dijk N; de Velasco Oria de Rueda G; Necchi A; Lavaud P; Morales-Barrera R; Alonso Gordoa T; Maroto P; Ravaud A; Durán I; Szabados B; Castellano D; Giannatempo P; Loriot Y; Carles J; Anguera Palacios G; Lefort F; Raggi D; Gross Goupil M; Powles T; Van der Heijden MS
Eur Urol; 2020 Feb; 77(2):269-276. PubMed ID: 31699525
[TBL] [Abstract][Full Text] [Related]
18. A New Strategy Toward B Cell-Based Cancer Vaccines by Active Immunization With Mimotopes of Immune Checkpoint Inhibitors.
Tobias J; Battin C; De Sousa Linhares A; Lebens M; Baier K; Ambroz K; Drinić M; Högler S; Inic-Kanada A; Garner-Spitzer E; Preusser M; Kenner L; Kundi M; Zielinski CC; Steinberger P; Wiedermann U
Front Immunol; 2020; 11():895. PubMed ID: 32528470
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic vaccines increase the response to PD-L1 blockade in immunogenic and poorly immunogenic tumors.
Feola S; Capasso C; Fusciello M; Martins B; Tähtinen S; Medeot M; Carpi S; Frascaro F; Ylosmäki E; Peltonen K; Pastore L; Cerullo V
Oncoimmunology; 2018; 7(8):e1457596. PubMed ID: 30221051
[TBL] [Abstract][Full Text] [Related]
20. Combined Inhibition of TGF-β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models.
Sow HS; Ren J; Camps M; Ossendorp F; Ten Dijke P
Cells; 2019 Apr; 8(4):. PubMed ID: 30959852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]